Status of uric acid management in hypertensive subjects

Hypertension Research

Volumn 30, Issue 6, 2007, Pages 549-554

  Yamamoto, Yasutaka ^a   Matsubara, Koichi ^b   Igawa, Go ^b   Kaetsu, Yasuhiro ^c   Sugihara, Shinobu ^a   Matsuura, Takashi ^a   Ando, Fumihiro ^a   Sonoyama, Kazuhiko ^b   Hamada, Toshihiro ^b   Ogino, Kazuhide ^b   Igawa, Osamu ^b   Shigemasa, Chiaki ^c   Hisatome, Ichiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY HOSPITAL   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Cross sectional investigation; Hypertension; Hyperuricemia; Uric acid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

AGED; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITAL PHYSICIAN; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIVATE PRACTICE; PROTEINURIA; SEX DIFFERENCE; SMOKING;

AGED; AGED, 80 AND OVER; CARDIOLOGY; CROSS-SECTIONAL STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; INSTITUTIONAL PRACTICE; JAPAN; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRIVATE PRACTICE; URIC ACID; URICOSURIC AGENTS; XANTHINE OXIDASE;

EID: 34447547505     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.549     Document Type: Article

References (26)

1. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-464.
2. Johnson RJ, Kang DH, Feig D, et al: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
3. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
4. Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epiderniologic Follow-Up Study. Am J Epidemiol 1995; 141: 637-64.
5. Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
6. Tomita M, Mizuno S, Yamanaka H, et al: Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10: 403-409.
7. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078.
8. Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1154.
9. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37: 1069-1074.
10. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
11. Mazzali M, Hughes J, Kim YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
12. Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL: Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005; 45: 34-38.
13. Yamamoto Y, Ogino K, Igawa G, et al: Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats. Hypertens Res 2006; 29: 915-921.
14. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8608.
15. Committee for the Preparation of Guidelines for the Management of Hyperuricemia and Gout, Japanese Society of Gout and Nucleic Acid Metabolism: Guidelines for the Management of Hyperuricemia and Gout. Tokyo, Japanese Society of Gout and Nucleic Acid Metabolism, 2002.
16. Yamamoto Y, Sonoyama K, Matsubara. K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717-725.
17. ALLHAT Investigators: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
18. Mori H, Ukai H, Yamamoto H, et al: Current status of anti-hypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
19. Hoieggen A, Alderman MH, Kjeldsen SE, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
20. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y: Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202.
21. Anker SD, Doehner W, Rauchhaus M, et al: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997.
22. Doehner W, Schoene N, Rauchhaus. M, et al: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619-2624.
23. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
24. Japan Atherosclerotic Society: Japan Atherosclerotic Society (JAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease. Tokyo, Japan Atherosclerotic Society, 2002.
25. Ohtahara A, Hisatome I, Yamamoto Y, et al: The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers. J Hypertens 2001; 19: 575-582.
26. Nagahama K, Iseki K, Inoue T, Touma. T, Ikemiya Y, Takishita S: Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227-233.